Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- Hidehisa Saeki,
- Eita Fujimoto,
- Sei-ichiro Motegi
- and Naoko Kanda
Pages 156 to 165
Cite this article
- TAKAHASHI, Yohei,
- HAGINO, Teppei,
- UCHIYAMA, Akihiko,
- SAEKI, Hidehisa,
- FUJIMOTO, Eita,
- MOTEGI, Sei-ichiro
- and KANDA, Naoko,
- Takahashi, Yohei.,
- et al.
- Takahashi, Y.,
- Hagino, T.,
- Uchiyama, A.,
- Saeki, H.,
- Fujimoto, E.,
- Motegi, S.-i.
- and Kanda, N.
https://doi.org/10.1684/ejd.2026.5060
Article
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan
Latest publication
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Articles
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
- By Teppei Hagino,
- Marina Onda,
- Hidehisa Saeki,
- et al.
In European Journal of Dermatology (2024/5 Vol. 34)
Articles
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of dupilumab in Japanese paediatric patients with atopic dermatitis: a multiple-centre retrospective study in a real-life setting in Gunma Prefecture
- By Akihiko Uchiyama,
- Mai Ishikawa,
- Keiji Kosaka
- et al.
In European Journal of Dermatology (2025/3 Vol. 35)
Articles
Department of Dermatology, Nippon Medical School, Tokyo, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
- By Teppei Hagino,
- Marina Onda,
- Hidehisa Saeki,
- et al.
In European Journal of Dermatology (2024/5 Vol. 34)
Articles
Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
- By Teppei Hagino,
- Marina Onda,
- Hidehisa Saeki,
- et al.
In European Journal of Dermatology (2024/5 Vol. 34)
Articles
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of dupilumab in Japanese paediatric patients with atopic dermatitis: a multiple-centre retrospective study in a real-life setting in Gunma Prefecture
- By Akihiko Uchiyama,
- Mai Ishikawa,
- Keiji Kosaka
- et al.
In European Journal of Dermatology (2025/3 Vol. 35)
Articles
Department of Dermatology, Nippon Medical School, Tokyo, Japan
Latest publications
Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)
- By Yohei Takahashi,
- Teppei Hagino,
- Akihiko Uchiyama,
- et al.
In European Journal of Dermatology (2026/2 Vol. 36)
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
- By Teppei Hagino,
- Marina Onda,
- Hidehisa Saeki,
- et al.
In European Journal of Dermatology (2024/5 Vol. 34)